Cyclacel Pharmaceuticals, Inc. (CYCC) Announces Publication of Phase 2 Results for Sapacitabine in Elderly AML Patients in the Lancet Oncology  
11/1/2012 7:03:32 AM

BERKELEY HEIGHTS, N.J., Nov. 1, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), today announced the publication of results from a Phase 2 randomized trial of single-agent sapacitabine in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) or AML in first relapse. The study, published in The Lancet Oncology, demonstrates the safety and efficacy of sapacitabine in this patient population.